George D. Demetri, Md: Clinical Trials On Soft Tissue Sarcoma, Design And Objetives

George D. Demetri, MD: Clinical trials on Soft Tissue Sarcoma, design and objetives

Dr. George D. Demetri on Trabectedin for Sarcomas

The Convergence of Targeted Therapies and Immuno-Oncology in Sarcoma

Targeted Oncology

Dr. George D. Demetri on the Importance of Collaboration in Sarcoma

Dr. Demetri on the Evolving Field of Sarcoma

Dr. George Demetri on the Mutagenic Properties and Future Potentials of Dacarbazine

Targeted Oncology

Dr. George D. Demetri on the Impact of Sarcoma Subtyping on Other Cancers

Dr. George Discusses Ongoing Trials in Soft Tissue Sarcoma

Sequencing Decisions in Soft Tissue Sarcoma

Dr. George Demetri Discusses Regorafenib for Patients with GIST Trial Results

Evofosfamide Versus Ifosfamide Patient Selection in Soft Tissue Sarcoma

Dr. George Demetri on blood test for cancer mutations | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. George Demetri Explains the Side Effects Associated With Regorafenib

Seeking a Second Opinion Before Sarcoma Treatment Begins

Dr. George Demetri on Being Named a Giant of Cancer Care

Soft-Tissue Sarcoma: Looking Ahead

Getting the Right Diagnosis and Treatment

Using Clinical Trials to Fight Sarcoma

Breakthroughs for Physicians

The role of biomarkers in soft tissue sarcoma treatment and research

Sarcoma clinical trials: What to expect | OSUCCC – James

Ohio State University Comprehensive Cancer Center-James Cancer Hospital & Solove Research Institute